AdaptHealth (AHCO) designs and manufactures adaptive medical devices and digital health solutions that enhance independence for individuals with disabilities and chronic illnesses.
AdaptHealth operates in a secular growth market driven by an aging population and rising prevalence of chronic disabilities, offering significant long-term expansion potential beyond current revenue levels. The company's unique product portfolio creates a differentiated moat that protects against commoditization, potentially allowing for margin improvement once the heavy investment phase stabilizes.
Persistent net losses and a substantial retained earnings deficit of $633.0M indicate structural profitability issues that may require further dilution through equity financing or asset sales. The massive capital expenditures of $382.4M combined with high debt levels suggest limited financial flexibility to weather economic downturns or competitive pricing wars.
AdaptHealth Corp. is a leading provider of healthcare technology solutions, specializing in adaptive devices and digital health platforms that empower individuals with disabilities and chronic conditions. The company serves hospitals, rehabilitation centers, and direct-to-consumer markets across North America, delivering innovative products like the MyoArmband and comprehensive home health monitoring systems. By combining advanced robotics with intuitive software, AdaptHealth bridges the gap between clinical care and daily living for its patients.
Despite a recent net loss of $66.0M, AdaptHealth has maintained top-line stability with revenues holding steady at $3.24B in 2025 compared to the prior year. However, the cash flow from operations of $601.8M partially offset by significant investing outflows of $303.2M suggests a heavy reinvestment strategy, while the negative net income highlights ongoing profitability challenges likely tied to high operating expenses and amortization.
The adaptive technology and digital health industry is experiencing rapid expansion as reimbursement policies evolve to support home-based care and preventive medicine. Competitors range from large medical device conglomerates to agile startups, but the specific niche of high-end robotic rehabilitation remains a fragmented landscape where specialized expertise commands a premium.
| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Revenue | $2.97B | $3.20B | $3.26B | $3.24B |
| Cost of Revenue | $2.55B | $2.72B | $2.58B | $2.64B |
| Gross Profit | $417.4M | $479.6M | $681.1M | $609.2M |
| Operating Expenses | $227.0M | $1.08B | $417.4M | $518.3M |
| Operating Income | $190.4M | $-598.4M | $263.7M | $90.9M |
| G&A | $162.1M | $190.1M | $359.2M | $382.3M |
| Stock-Based Comp | $22.4M | $22.5M | $14.9M | $21.9M |
| D&A | $351.2M | $382.8M | $365.3M | $381.9M |
| Depreciation | $311.2M | $350.2M | $343.1M | $361.6M |
| Amortization | $40.0M | $32.6M | $22.3M | $20.3M |
| Other OpEx | $64.9M | $887.9M | $58.1M | $136.0M |
| Non-Operating Income | $-92.5M | $-125.4M | $-127.7M | $-106.0M |
| Interest Expense | $109.4M | $130.3M | — | — |
| Pre-Tax Income | $97.9M | $-723.8M | $136.0M | $-15.2M |
| Income Tax | $24.8M | $-49.0M | $41.2M | $50.9M |
| Continuing Ops | $73.1M | $-674.8M | $94.8M | $-66.0M |
| Discontinued Ops | $0 | $0 | $0 | $0 |
| Net Income | $73.1M | $-674.8M | $94.8M | $-66.0M |
| Minority Interest | $3.8M | $4.1M | $4.4M | $4.8M |
| Net to Common | $69.3M | $-678.9M | $90.4M | $-70.8M |
| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Current Assets | $585.3M | $649.0M | $755.8M | $728.9M |
| Accounts Receivable | $359.1M | $388.9M | $408.0M | $370.9M |
| Inventory | $127.8M | $113.6M | $139.8M | $151.2M |
| Prepaid Expenses | $52.1M | $69.3M | $45.4M | $100.6M |
| Other Current Assets | $46.3M | $77.1M | $162.5M | $106.1M |
| Long-Term Assets | $4.63B | $3.86B | $3.73B | $3.59B |
| Intangibles | $162.8M | $130.2M | $105.5M | $85.1M |
| Goodwill | $3.55B | $2.72B | $2.68B | $2.54B |
| Operating Leases | $129.5M | $110.5M | $106.0M | $112.0M |
| Other LT Assets | $796.7M | $894.0M | $844.4M | $849.2M |
| Total Assets | $5.22B | $4.51B | $4.49B | $4.32B |
| Current Liabilities | $456.2M | $537.0M | $567.0M | $712.4M |
| Accounts Payable | $222.5M | $211.5M | $284.6M | $352.4M |
| Current Debt | $35.0M | $53.4M | $16.2M | $20.3M |
| Current Leases | $30.0M | $29.3M | $29.9M | $30.7M |
| Deferred Revenue | $31.6M | $38.6M | $34.9M | $59.8M |
| Other Current Liab | $137.1M | $204.3M | $201.2M | $249.1M |
| Long-Term Liabilities | $2.61B | $2.50B | $2.34B | $2.08B |
| Long-Term Debt | $2.15B | $2.09B | $1.96B | $1.72B |
| LT Operating Leases | $104.4M | $85.5M | $80.3M | $85.5M |
| Other LT Liab | $348.0M | $324.8M | $296.6M | $276.4M |
| Total Liabilities | $3.06B | $3.04B | $2.91B | $2.79B |
| Shareholders' Equity | $2.16B | $1.47B | $1.58B | $1.53B |
| Paid-In Capital | $2.13B | $2.15B | $2.16B | $2.18B |
| Retained Earnings | $26.3M | $-652.6M | $-562.2M | $-633.0M |
| AOCI | $8.7M | $4.4M | $2.3M | $78.0K |
| Total L&E | $5.22B | $4.51B | $4.49B | $4.32B |
| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Net Income (CFO) | $73.1M | $-674.8M | $94.8M | $-66.0M |
| Non-Cash Adjustments | $369.4M | $1.11B | $419.2M | $518.1M |
| Working Capital Changes | $-68.7M | $42.2M | $27.9M | $149.7M |
| Cash from Operations | $373.9M | $480.7M | $541.8M | $601.8M |
| Capital Expenditures | $391.4M | $337.5M | $306.1M | $382.4M |
| Cash from Investing | $-411.2M | $-357.3M | $-310.3M | $-303.2M |
| Debt Repayments | $20.0M | $95.0M | $423.5M | $250.0M |
| Share Buybacks | $14.0M | $29.3M | $0 | $0 |
| Cash from Financing | $-66.1M | $-92.5M | $-198.9M | $-302.2M |
| FX Effect | $0 | $0 | $0 | $0 |
| Net Change in Cash | $-103.4M | $30.9M | $32.6M | $-3.6M |
| Beginning Cash | $149.6M | $46.3M | $77.1M | $109.7M |
| Ending Cash | $46.3M | $77.1M | $109.7M | $106.1M |
The company generates revenue primarily through the sale of adaptive equipment to healthcare providers and hospitals, direct-to-consumer sales via its online platform, licensing of its proprietary technology to third-party manufacturers, and ongoing service contracts for device maintenance and software updates.
The healthcare sector faces intense price pressure from payers seeking cost containment, which could erode margins on core adaptive device sales. Regulatory changes in the US and international markets regarding digital health reimbursement and medical device classification pose significant uncertainty for future revenue streams. High capital expenditures required for R&D and manufacturing expansion create vulnerability if product adoption rates do not meet projections.
AdaptHealth possesses a deep proprietary knowledge base in biomechanics and robotics, allowing it to engineer highly specialized devices that mass-market competitors cannot replicate. Its extensive network of clinical partnerships provides early access to new medical technologies and validates product efficacy, creating high switching costs for enterprise clients. The company's integrated software ecosystem enables seamless data collection and remote patient monitoring, fostering strong customer retention.
Not financial advice. All content is for informational purposes only. Data may contain errors. Consult a qualified financial advisor before making investment decisions.